Blend Therapeutics is a biopharmaceutical company discovering new classes of medicines to treat debilitating diseases. The company is pioneering an integrative way to discover molecular entities with new mechanisms of action purposely designed for our proprietary nanoparticles. By synergistically developing both the molecule and the nanoparticle together they can make medicines more targeted, more effective and more tolerable.
A leading provider of cutting-edge technologies enabling researchers in the life sciences to create life-saving and enhancing medicines and diagnostic tests more quickly and efficiently. Caliper has compiled numerous best-in-class solutions and is aggressively innovating new technologies to bridge the gaps that exist in bringing in vitro assays to in vivo results and ultimately into cures for human disease.
A a medical device company that has developed and is commercializing a proprietary wireless sensing and communication technology for the human body. The company's sensors are designed and manufactured using microelectromechanical systems, or MEMS, technology, which enables the fabrication of millimeter-scale devices with internal features in the nanometer to micrometer range.
Celera has a successful molecular diagnostics business and powerful genomic and proteomic discovery platforms that have identified and validated new drug targets and biomarkers that will advance the practice of Targeted Medicine.
Celsense is a biotechnology company offering novel MRI contrast agents (fluorochemical nanoparticles) that allow scientists and clinicians to monitor the position and quantity of transplanted cells non-invasively in vivo.
Chemicon offers molecular biology research tools. Included are mRNA expression analysis assays via RT-PCR and PCR amplication methods for apoptosis, cancer, cytokines, signal transduction, MMPs and ECM using colorimetric or bioluminescent formats
Developed a technology to compact DNA into complexes containing only a single molecule of DNA, resulting in a volume 30-1000 times smaller than other complexes. This simple difference makes Copernicus' "DNA nanoparticles" highly stable and uniquely able to deliver DNA to the nuclei of non-dividing human cells - which includes most cells in the body.
Covaris, Inc. is a life science instrument company. Its proprietary instrument platform, based on patented Adaptive Focused Acoustic (AFA) technology brings unsurpassed speed and efficiency to biological and chemical sample preparation. The AFA process, based on shock wave physics, delivers controlled, precise and accurate energy to biological and chemical samples.
Delpor develops the next generation Drug Delivery Systems that improve the clinical and commercial value of drugs and biopharmaceuticals. The company also has developed a microfabricated nanopore device for the sustained release of therapeutic agents.
The company's NLP technology produces a generation of particles which retains the strength of the Dermazone Solutions' (SDMC) technologies, but includes the ability to produce particles of 60 nanometers to 150 nanometers which are optically clear. The use of this generation of lipid-based particle delivery system provides the ability to control the size of the final particle by controlling the number of NLPs used to assemble the finished particle. This system maintains very high loading capacity of passenger molecules and uses only safe, all natural ingredients to form both the NLPs and the final delivery system.
Digilab offers a wide range of sample preparation and liquid handling tool, and a imaging and spectroscopy products for sample identification for the Life Science, Analytical Chemistry and Diagnostic markets.
Dune Sciences is an emerging technology company specializing in products and services that will facilitate the development and commercialization of nano-enabled products. The company employs several patented and patent-pending technologies to engineer interfaces for the integration of new materials and devices in medicine, bionanotechnology, energy technologies, and nanoscience.
Ensemble Therapeutics is utilizing DNA Programmed Chemistry (DPC), an innovative method for creating new chemical bonds. Ensemble integrates DPC into a nanoscale selection system that combines chemistry, biology and informatics to discover novel compounds.
The company is focused on the use of fullerene carbon nanotubes for novel therapeutic applications specifically in the area of cancer treatment. The company's extensive carbon nanotube-related, worldwide intellectual property portfolio includes discoveries by the late Nobel Prize winner Dr Rick Smalley. The use of fullerene carbon nanotubes has the goal of solving two important problems for many cancer therapeutics, that of delivering large active agents into the desired location and of protecting normal tissue from the active agent during delivery.